DSS
DSS, Inc.0.9516
-0.0433-4.35%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
8.65MP/E (TTM)
-Basic EPS (TTM)
-5.67Dividend Yield
0%Recent Filings
8-K
8-K
Annual meeting elects directors
DSS, Inc. held its 2025 annual stockholder meeting on December 3, with 83.80% of shares present. Stockholders elected seven directors—Ambrose Chan Heng Fai, José Escudero, and five others—each garnering over 6 million FOR votes despite 1.37 million broker non-votes. They ratified HTL International, LLC as auditors for fiscal 2025 and advisory approved executive compensation. Board continuity locked in.
10-Q
Q3 FY2025 results
DSS revenue climbed 14% y/y to $6.4M in Q3 ended September 30, 2025, with printed products up 3% y/y to $5.0M and securities commissions surging 188% y/y, yet operating loss narrowed to $3.2M from $4.7M on cost discipline. Nine-month revenue rose 22% y/y to $16.6M, operating loss improved to $10.4M from $14.3M, and diluted EPS loss held at $(1.03) across 8.96M shares (derived). Cash fell to $7.0M after $7.6M operating outflow, offset by $12.1M investing inflow from $9.0M real estate sale; total debt sat at $50.2M with key facilities in default. Investors trimmed Impact BioMedical stake for $2.4M. Tenant licensing issues threaten REIT rents.
10-Q
Q2 FY2025 results
DSS revenue climbed 26% y/y to $5.3M in Q2 ended June 30, 2025, driven by printed products up 21% y/y to $4.3M and rental income doubling to $715K, yet operating loss narrowed to $3.4M from $4.9M as costs fell 5%. Six-month revenue rose 27% y/y to $10.2M, with operating loss shrinking to $7.2M (derived) from $9.6M; net loss improved to $2.6M, narrowed by $1.6M gain on investments but widened by $600K intangible impairment and $727K real estate sale loss. Cash swung to $430K positive from operations; investing gained $10.1M on $9.5M Plano facility sale, financing burned $12.5M on debt paydown, leaving $9.5M cash against $43.9M debt (much past due). Losses persist across segments. Customer concentration risks linger.
8-K
DSS converts $12M debt to shares
DSS, Inc. converted $12 million in outstanding debt from Impact Biomedical into 31,939,778 shares of its common stock on July 21, 2025, fully settling the revolving note originally issued March 31, 2023, and amended January 18, 2024. Debt wiped clean. This swap bolsters DSS's balance sheet while tying it deeper to Impact's fortunes.
IPO
Website
Employees
Sector
Industry
AVY
Avery Dennison Corporation
183.12-0.57
DAR
Darling Ingredients Inc.
35.03-1.16
DQWS
Dswiss Inc
0.04+0.00
GPK
Graphic Packaging Holding Compa
15.38-0.02
IP
International Paper Company
38.61+0.01
KRT
Karat Packaging Inc.
23.36+0.43
PACK
Ranpak Holdings Corp
5.41-0.04
PKG
Packaging Corporation of Americ
203.66-0.82
SLGN
Silgan Holdings Inc.
40.58+0.18
SW
Smurfit WestRock plc
37.69+0.15